Table S3. Therapeutic information of patients receiving ICIs.
| Therapeutic information | n (%) |
| ICI, immune checkpoint inhibitor; HER2, human epidermal growth factor receptor 2; ORR, objective response rate; DCR, disease control rate; irPFS, immunotherapy-related progression-free survival; 95% CI, 95% confidence interval. | |
| Line | |
| 1st | 47 (56.6) |
| ≥2nd | 36 (43.4) |
| Regimen | |
| ICI | 12 (14.5) |
| ICI+ICI | 3 (3.6) |
| ICI + chemotherapy | 44 (53.0) |
| ICI + anti-HER2 + chemotherapy | 11 (13.3) |
| ICI + anti-angiogenesis + chemotherapy | 13 (15.7) |
| ORR (%) | |
| 1st-line | 46.8 |
| ≥2nd-line | 22.2 |
| DCR (%) | |
| 1st-line | 87.2 |
| 2nd-line | 55.6 |
| irPFS [median (95% CI)] (month) | |
| 1st-line | 8.1 (7.0−10.1) |
| ≥2nd-line | 3.6 (2.6−5.9) |